Evaluation of Right Ventricular Systolic Function by TAPSE Parameter From Subcostal View

Sponsor
Emergency Medical Service of the Central Bohemian Region, Czech Republic (Other)
Overall Status
Unknown status
CT.gov ID
NCT04490538
Collaborator
Masaryk Hospital Usti nad Labem (Other)
100
1
3.2
31.7

Study Details

Study Description

Brief Summary

The purpose of this study is to validate a new echocardiographic parameter evaluating right ventricular function.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Transthoracic echocardiography

Detailed Description

The key conventional echocardiographic parameter evaluating right ventricular systolic function is the tricuspid annular plane systolic excursion (TAPSE). It is measured in apical four chamber view by conventional M-mode imaging. Other echocardiographic parameters of right ventricular systolic function (Fractional Area Change; Tricuspid Lateral Annular Systolic Velocity; Right Ventricular Index of Myocardial Performance) are evaluated in apical four chamber view as well. However, this view might not be clearly visible in the clinical setting of critical illness and subcostal view is often preferred for its higher quality. Unfortunately, conventional M-mode can not be used for measurement in this view but anatomical M-mode imaging can. Therefore, the investigators decided to evaluate whether TAPSE measured in subcostal view by anatomical M-mode (sTAPSE) correlates with conventional TAPSE and whether reliably reflects systolic right ventricular function.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Echocardiographic Evaluation of Right Ventricular Systolic Function by TAPSE Parameter Measured From Subcostal View Using Anatomical M-mode - Validation Clinical Study
Actual Study Start Date :
Jul 27, 2020
Anticipated Primary Completion Date :
Sep 30, 2020
Anticipated Study Completion Date :
Oct 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Critically ill patients

Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.

Diagnostic Test: Transthoracic echocardiography
Conventional transthoracic echocardiographic examination at the intensive care unit.

Outcome Measures

Primary Outcome Measures

  1. Validity of sTAPSE in prediction of right ventricular systolic dysfunction [During the intervention]

    sTAPSE is a new potential echocardiographic parameter of right ventricular systolic function measurable from subcostal view.

Secondary Outcome Measures

  1. Correlation of sTAPSE with conventional TAPSE [During the intervention]

    sTAPSE is a new potential echocardiographic parameter of right ventricular systolic function measurable from subcostal view.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Inpatients

  • All patients hospitalised in intensive care unit indicated for transthoracic echocardiography examination

Exclusion Criteria:
  • Age <18 years

  • Insufficient imaging quality of transthoracic echocardiography

  • Refusal of echocardiographic examination by patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 Masaryk Hospital Usti nad Labem Usti nad Labem Czechia 40113

Sponsors and Collaborators

  • Emergency Medical Service of the Central Bohemian Region, Czech Republic
  • Masaryk Hospital Usti nad Labem

Investigators

  • Principal Investigator: Roman Skulec, MD, PhD, Masaryk Hospital Usti nad Labem

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Roman Skulec, Principal investigator, Masaryk Hospital Usti nad Labem
ClinicalTrials.gov Identifier:
NCT04490538
Other Study ID Numbers:
  • 284/34
First Posted:
Jul 29, 2020
Last Update Posted:
Aug 19, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2020